Précisez une action ou une cryptomonnaie dans la barre de recherche pour obtenir un récapitulatif
Bioxytran Inc
BIXTBioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company's lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin-Rx, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin for treatment of mild to moderate cases of Covid-19. The company was founded in 2008 and is headquartered in Needham, Massachusetts. Address: 75 2nd Avenue, Needham, MA, United States, 02494
Analytics
Objectif de Cours de WallStreet
2.71 USDRatio C/B
–Rendement du dividende
–Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Chiffres clés BIXT
Analyse des dividendes BIXT
Croissance des dividendes sur 5 ans
–Croissance continue
–Ratio de distribution Moyenne sur 5 ans
–Historique des dividendes BIXT
Valorisation des titres BIXT
financières BIXT
Résultats | 2019 | Dynamique |